Compare Regeneron Pharmaceuticals Inc (REGN) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ross Stores, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Ross Stores, Inc. trades at $238.21 (market cap $75.63B). The key difference: Regeneron Pharmaceuticals Inc and Ross Stores, Inc. are close in size by market cap, and Ross Stores, Inc. pays the higher dividend (0.75%). Which is the better fit depends on your goals.
| REGN | ROST | |
|---|---|---|
Market Cap | $70.79B | $75.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $240.13 |
52-Week Low | $545.46 | $135.76 |
Enterprise Value | $64.74B | $76.23B |
Dividend Yield | 0.56% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Ross Stores (ROST) trades at $235.78, up 1.05% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q1 2026 results with 21% sales growth and expanding margins, while expanding its store footprint with 47 new locations in mid-2026. Valuation metrics show a P/E of 32.93 and robust profitability with a 38.98% ROE, though the stock trades near analyst price targets.
The outlook remains positive due to consistent earnings outperformance and store expansion, but risks include high valuation multiples and competitive retail pressures. Analyst consensus is bullish with a $259 price target, suggesting moderate upside potential from current levels amid broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
